The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.

Belén Garijo, CEO of Merck KGaA, weighs in on Europe's competitiveness and the pharma giant's preparations for the impact of ...

Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the introduction of a Caregiver ...

Merck KGaA (OTCMKTS:MKGAF – Get Free Report)’s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $147.57 and traded as low as ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...